These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

181 related items for PubMed ID: 2112054

  • 1. Early phase II Gynecologic Oncology Group experience with ifosfamide/mesna in gynecologic malignancies.
    Sutton GP, Blessing JA, Photopulos G, Berman ML, Homesley HD.
    Cancer Chemother Pharmacol; 1990; 26 Suppl():S55-8. PubMed ID: 2112054
    [Abstract] [Full Text] [Related]

  • 2. Phase II experience with ifosfamide/mesna in gynecologic malignancies: preliminary report of Gynecologic Oncology Group studies.
    Sutton GP, Blessing JA, Photopulos G, Berman ML, Homesley HD.
    Semin Oncol; 1989 Feb; 16(1 Suppl 3):68-72. PubMed ID: 2539647
    [Abstract] [Full Text] [Related]

  • 3. Gynecologic Oncology Group experience with ifosfamide.
    Sutton GP, Blessing JA, Photopulos G, Berman ML, Homesley HD.
    Semin Oncol; 1990 Apr; 17(2 Suppl 4):6-10. PubMed ID: 2159188
    [Abstract] [Full Text] [Related]

  • 4. Phase II trial of ifosfamide and mesna in advanced ovarian carcinoma: a Gynecologic Oncology Group Study.
    Sutton GP, Blessing JA, Homesley HD, Berman ML, Malfetano J.
    J Clin Oncol; 1989 Nov; 7(11):1672-6. PubMed ID: 2509641
    [Abstract] [Full Text] [Related]

  • 5. Phase II trial of ifosfamide and mesna in patients with advanced or recurrent squamous carcinoma of the cervix who had never received chemotherapy: a Gynecologic Oncology Group study.
    Sutton GP, Blessing JA, McGuire WP, Patton T, Look KY.
    Am J Obstet Gynecol; 1993 Mar; 168(3 Pt 1):805-7. PubMed ID: 8456884
    [Abstract] [Full Text] [Related]

  • 6. Phase II study of ifosfamide and mesna in nonsquamous carcinoma of the cervix: a Gynecologic Oncology Group study.
    Sutton GP, Blessing JA, DiSaia PJ, McGuire WP.
    Gynecol Oncol; 1993 Apr; 49(1):48-50. PubMed ID: 8482560
    [Abstract] [Full Text] [Related]

  • 7. Phase II trial of ifosfamide and mesna in mixed mesodermal tumors of the uterus (a Gynecologic Oncology Group study).
    Sutton GP, Blessing JA, Rosenshein N, Photopulos G, DiSaia PJ.
    Am J Obstet Gynecol; 1989 Aug; 161(2):309-12. PubMed ID: 2548382
    [Abstract] [Full Text] [Related]

  • 8. Gynecologic Oncology Group studies with ifosfamide.
    Sutton GP, Blessing JA, Manetta A, Homesley H, McGuire W.
    Semin Oncol; 1992 Dec; 19(6 Suppl 12):31-4. PubMed ID: 1485172
    [Abstract] [Full Text] [Related]

  • 9. A phase II trial of ifosfamide and mesna in patients with advanced or recurrent mixed mesodermal tumors of the ovary previously treated with platinum-based chemotherapy: a Gynecologic Oncology Group study.
    Sutton GP, Blessing JA, Homesley HD, Malfetano JH.
    Gynecol Oncol; 1994 Apr; 53(1):24-6. PubMed ID: 8175017
    [Abstract] [Full Text] [Related]

  • 10. Ifosfamide and mesna at high doses for the treatment of cancer of the cervix: a GETLAC study.
    Cervellino JC, Araujo CE, Pirisi C, Sanchez O, Brosto M, Rossi R.
    Cancer Chemother Pharmacol; 1990 Apr; 26 Suppl():S1-3. PubMed ID: 2112052
    [Abstract] [Full Text] [Related]

  • 11. Phase II study of ifosfamide and mesna in patients with previously-treated carcinoma of the cervix. A Gynecologic Oncology Group study.
    Sutton GP, Blessing JA, Adcock L, Webster KD, DeEulis T.
    Invest New Drugs; 1989 Nov; 7(4):341-3. PubMed ID: 2513286
    [Abstract] [Full Text] [Related]

  • 12. Phase II study of ifosfamide and mesna in refractory adenocarcinoma of the endometrium. A Gynecologic Oncology Group study.
    Sutton GP, Blessing JA, Homesley HD, McGuire WP, Adcock L.
    Cancer; 1994 Mar 01; 73(5):1453-5. PubMed ID: 8111713
    [Abstract] [Full Text] [Related]

  • 13. High-dose alkylation therapy using ifosfamide infusion with mesna in the treatment of adult advanced soft-tissue sarcoma.
    Stuart-Harris RC, Harper PG, Parsons CA, Kaye SB, Mooney CA, Gowing NF, Wiltshaw E.
    Cancer Chemother Pharmacol; 1983 Mar 01; 11(2):69-72. PubMed ID: 6414732
    [Abstract] [Full Text] [Related]

  • 14. High-dose ifosfamide with mesna uroprotection: a phase I study.
    Elias AD, Eder JP, Shea T, Begg CB, Frei E, Antman KH.
    J Clin Oncol; 1990 Jan 01; 8(1):170-8. PubMed ID: 2104923
    [Abstract] [Full Text] [Related]

  • 15. Etoposide (VP-16), ifosfamide/mesna, and cisplatin chemotherapy for advanced and recurrent carcinoma of the cervix.
    Kredentser DC.
    Gynecol Oncol; 1991 Nov 01; 43(2):145-8. PubMed ID: 1743556
    [Abstract] [Full Text] [Related]

  • 16. Ifosfamide treatment of recurrent or metastatic endometrial stromal sarcomas previously unexposed to chemotherapy: a study of the Gynecologic Oncology Group.
    Sutton G, Blessing JA, Park R, DiSaia PJ, Rosenshein N.
    Obstet Gynecol; 1996 May 01; 87(5 Pt 1):747-50. PubMed ID: 8677079
    [Abstract] [Full Text] [Related]

  • 17. A phase II study of ifosfamide/mesna with doxorubicin for adult soft tissue sarcoma.
    Cantwell BM, Carmichael J, Ghani S, Harris AL.
    Cancer Chemother Pharmacol; 1988 May 01; 21(1):49-52. PubMed ID: 3124971
    [Abstract] [Full Text] [Related]

  • 18. High-dose ifosfamide and mesna in advanced breast cancer. A phase II study.
    Sanchiz F, Milla A.
    Cancer Chemother Pharmacol; 1990 May 01; 26 Suppl():S91-2. PubMed ID: 2112057
    [Abstract] [Full Text] [Related]

  • 19. A phase II Gynecologic Oncology Group trial of ifosfamide and mesna in advanced or recurrent adenocarcinoma of the endometrium.
    Sutton GP, Blessing JA, DeMars LR, Moore D, Burke TW, Grendys EC.
    Gynecol Oncol; 1996 Oct 01; 63(1):25-7. PubMed ID: 8898163
    [Abstract] [Full Text] [Related]

  • 20. Ifosfamide given as a 24-h infusion with mesna in patients with recurrent ovarian cancer: preliminary results.
    Willemse PH, vd Burg ME, vd Gaast A, Neijt JP, ten Bokkel Huinink WW, Aalders JG, de Vries EG.
    Cancer Chemother Pharmacol; 1990 Oct 01; 26 Suppl():S51-4. PubMed ID: 2112053
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 10.